Lifelink Systems has announced a collaboration with Genentech to provide a suite of conversational technology solutions that will support a broad range of patient experience initiatives at the biotechnology leader. Lifelink Systems will provide Genentech with a platform to power smart digital assistants to help clinical trial participants, patients, caregivers, and providers to receive personalized assistance and support related to clinical research programs and approved therapies.
Lifelink Systems technology has configurations that are designed to support clinical trial programs and medical information desks.
The Lifelink Systems technology will also be used by Genentech to help improve clinical trial diversity and inclusive research efforts. People of color remain vastly underrepresented in clinical research and Genentech is on a mission to change that.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.